APP transgenic mouse models and their use in drug discovery to evaluate amyloid-β lowering therapeutics

CNS and Neurological Disorders - Drug Targets

Volumn 9, Issue 4, 2010, Pages 395-402

  Hussain, Ishrut ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Alzheimer's disease; Amyloid precursor protein; Amyloid ; Presenilin; Tau; Transgenic mouse

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ANTIINFLAMMATORY AGENT; AZD 103; BAPINEUZUMAB; BEGACESTAT; CAFFEINE; CLIOQUINOL; CTS 2116; CURCUMIN; DP 109; E 2012; EPIGALLOCATECHIN GALLATE; GAMMA SECRETASE INHIBITOR; GSK 188909; HOMOTAURINE; HYPOCHOLESTEROLEMIC AGENT; INOSITOL; LY 2062430; MUSCARINIC AGENT; MUTANT PROTEIN; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; OM00 3; PBT 1; PBT 2; PF 04494700; PRESENILIN; SEMAGACESTAT; TARENFLURBIL; TAU PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR; SECRETASE;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; MENINGOENCEPHALITIS; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; SENILE PLAQUE; TRANSGENE; TRANSGENIC MOUSE; AMYLOID PLAQUE; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; METABOLISM; MOUSE; PROCEDURES;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; MICE; MICE, TRANSGENIC; NEUROFIBRILLARY TANGLES; PLAQUE, AMYLOID; RECEPTORS, IMMUNOLOGIC; TAU PROTEINS;

EID: 77954330734     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152710791556087     Document Type: Article

References (94)

1. Glenner, G.G.; Wong, C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Comm., 1984, 120, 885-890.
2. Goedert, M.; Wischik, C.M.; Crowther, R.A.; Walker, J.E.; Klug, A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc. Natl. Acad. Sci. USA, 1988, 85, 4051-4055.
3. Selkoe, D. J. Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. Annu. Rev. Cell Biol., 1994, 10, 373-403.
4. Selkoe, D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature, 1999, 399 (Suppl 6738), A23-A31.
5. Whitehouse, P.J.; Price, D.L.; Struble, R.G.; Clark, A.W.; Coyle, J.T.; Delon, M.R. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science, 1982, 215, 1237-1239.
6. Games, D.; Adams, D.; Alessandrini, R.; Barbour, R.; Berthelette, P.; Blackwell, C.; Carr, T.; Clemens, J.; Donaldson, T.; Gillespie, F.; Guido, T.; Hagopian, S.; Johnsonwood, K.; Khan, K.; Leed, M.; Leibowitz, P.; Lieberburg, I.; Little, S.; Masliah, E.; McConlogue, L.; Montoyazavala, M.; Mucke, L.; Paganini, L.; Penniman, E.; Power, M.; Schenk, D.; Seubert, P.; Snyder, B.; Soriano, F.; Tan, H.; Vitale, J.; Wadsworth, S.; Wolozin B.; Zhao, J. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta- amyloid precursor protein. Nature, 1995, 373, 523-527.
7. Hsiao, K.; Chapman, P.; Nilsen, S.; Eckman, C.; Harigaya, Y.; Younkin, S.; Yang, F.; Cole, G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science, 1996, 274, 99-102.
8. Sturchler-Pierrat, C.; Abramowski, D.; Duke, M.; Wiederhold, K.H.; Mistl, C.; Rothacher, S.; Ledermann, B.; Bürki, K.; Frey, P.; Paganetti, P.A.; Waridel, C.; Calhoun, M.E.; Jucker, M.; Probst, A.; Staufenbiel, M.; Sommer, B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. USA, 1997, 94, 13287-13292.
9. Moechars, D.; Dewachter, I.; Lorent, K.; Reverse, D.; Baekelandt, V.; Naidu, A.; Tesseur, I.; Spittaels, K.; Van den Haute, C.V.; Checler, F.; Godaux, E.; Cordell, B.; Van Leuven, F. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem., 1999, 274, 6483-6492.
10. Richardson, J.C.; Kendal, C.E.; Anderson, R.; Priest, F.; Gower, E.; Soden, P.; Gray, R.; Topps, S.; Howlett, D.R.; Lavender, D.; Clarke, N.J.; Barnes, J.C.; Haworth, R.; Stewart, M.G.; Rupniak, H.T.R. Ultrastructural and behavioural changes precede amyloid deposition in a transgenic model of Alzheimer's disease. Neuroscience, 2003, 122, 213-228.
11. Westerman, M.A.; Cooper-Blacketer, D.; Mariash, A.; Kotilinek, L.; Kawarabayashi, T.; Younkin, L.H.; Carlson, G.A.; Younkin, S.G.; Ashe, K.H. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci., 2002, 22, 1858-1867.
12. Van Dam, D.; D'Hooge, R.; Staufenbiel, M.; Van Ginneken, C.; Van Meir, F.; De Deyn, P.P. Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur. J. Neurosci., 2003, 17, 388-396.
13. Chishti, M.A.; Yang, D.S.; Janus, C.; Phinney, A.L.; Horne, P.; Pearson, J.; Strome, R.; Zuker, N.; Loukides, J.; French, J.; Turner, S.; Lozza, G.; Grilli, M.; Kunicki, S.; Morissette, C.; Paquette, J.; Gervais, F.; Bergeron, C.; Fraser, P.E.; Carlson, G.A.; George- Hyslop, P.S.; Westaway, D. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem., 2001, 276, 21562-21570.
14. Rockenstein, E.; Mallory, M.; Mante, M.; Sisk, A.; Masliaha E. Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42). J. Neurosci. Res., 2001, 66, 573-582.
15. Sherrington, R.; Rogaev, E.I.; Liang, Y.; Rogaeva, E.A.; Levesque, G.; Ikeda, M.; Chi, H.; Lin, C.; Li, G.; Holman, K.; Tsuda, T.; Mar, L.; Foncin, J.-F.; Bruni, A.C.; Montesi, M.P.; Sorbi, S.; Rainero, I.; Pinessi, L.; Nee, L.; Chumakov, I.; Pollen, D.; Brookes, A.; Sanseau, P.; Polinsky, R.J.; Wasco, W.; Da Silva, H.A.R.; Haines, J.L.; Pericak-Vance, M.A.; Tanzi, R.E.; Roses, A.D., Fraser, P.E.; Rommens, J.M.; St George-Hyslop, P.H. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature, 1995, 375, 754-760.
16. Scheuner, D.; Eckman, C.; Jensen, M.; Song, X.; Citron, M.; Suzuki, N.; Bird, T.D.; Hardy, J.; Hutton, M.; Kukull, W.; Larson, E.; Levy-Lahad, E.; Viitanen, M.; Peskind, E.; Poorkaj, P.; Schellenberg, G.; Tanzi, R.; Wasco, W.; Lannfelt, L.; Selkoe, D.; Younkin, S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med., 1996, 2, 864-870.
17. Borchelt, D.R.; Ratovitski, T.; van Lare, J.; Lee, M.K.; Gonzales, V.; Jenkins, N.A.; Copeland, N.G.; Price, D.L.; Sisodia, S.S. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron, 1997, 19, 939-945.
18. Holcomb, L.; Gordon, M.N.; McGowan, E.; Yu, X.; Benkovic, S.; Jantzen, P; Wright, K.; Saad, I.; Mueller, R.; Morgan, D.; Sanders, S.; Zehr, C.; O'Campo, K.; Hardy, J.; Prada, C.M.; Eckman, C.; Younkin, S.; Hsiao, K.; Duff, K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med., 1998, 4, 97-100.
19. Howlett, D.R.; Richardson, J.C.; Austin, A.; Parsons, A.A.; Bate, S.T.; Davies, D.C.; Gonzalez, M.I. Cognitive correlates of Abeta deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. Brain Res., 2004, 1017, 130-136.
20. Richards, J.G.; Higgins, G.A.; Ouagazzal, A.M.; Ozmen, L.; Kew, J.N.; Bohrmann, B.; Malherbe, P.; Brockhaus, M.; Loetscher, H.; Czech, C.; Huber, G.; Bluethmann, H.; Jacobsen, H.; Kemp, J.A. PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J. Neurosci., 2003, 23, 8989-9003.
21. Oakley, H.; Cole, S.L.; Logan, S.; Maus, E.; Shao, P.; Craft, J.; Guillozet-Bongaarts, A.; Ohno, M.; Disterhoft, J.; Van Eldik, L.; Berry, R.; Vassar, R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci., 2006, 26, 10129-10140.
22. Hutton, M.; Lendon, C.L.; Rizzu, P.; Baker, M.; Froelich, S.; Houlden, H.; Pickering-Brown, S.; Chakraverty, S.; Isaacs, A.; Grover, A.; Hackett, J.; Adamson, J.; Lincoln, S.; Dickson, D.; Davies, P.; Petersen, R.C.; Stevens, M.; de Graaff, E.; Wauters, E.; van Baren, J.; Hillebrand, M.; Joosse, M.; Kwon, J.M.; Nowotny, P.; Che, L.K.; Norton, J.; Morris, J.C.; Reed, L.A.; Trojanowski, J.; Basun, H.; Lannfelt, L.; Neystat, M.; Fahn, S.; Dark, F.; Tannenberg, T.; Dodd, P.R.; Hayward, N.; Kwok, J.B.; Schofield, P.R.; Andreadis, A.; Snowden, J.; Craufurd, D.; Neary, D.; Owen, F.; Oostra, B.A.; Hardy, J.; Goate, A.; van Swieten, J.; Mann, D.; Lynch, T.; Heutink, P. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature, 1998, 393, 702-705.
23. Poorkaj, P.; Bird, T.D.; Wijsman, E.; Nemens, E.; Garruto, R.M.; Anderson, L.; Andreadis, A.; Wiederholt, W.C.; Raskind, M.; Schellenberg, G.D. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol., 1998, 43, 815-825.
24. Lewis, J.; McGowan, E.; Rockwood, J.; Melrose, H.; Nacharaju, P.; Van Slegtenhorst, M.; Gwinn-Hardy, K.; Paul Murphy, M.; Baker, M.; Yu, X.; Duff, K.; Hardy, J.; Corral, A.; Lin, W.L.; Yen, S.H.; Dickson, D.W.; Davies, P.; Hutton, M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet., 2000, 25, 402-405.
25. Allen, B.; Ingram, E.; Takao, M.; Smith, M.J.; Jakes, R.; Virdee, K.; Yoshida, H.; Holzer, M.; Craxton, M.; Emson, P.C.; Atzori, C.; Migheli, A.; Crowther, R.A.; Ghetti, B.; Spillantini, M.G.; Goedert, M. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci., 2002, 22, 9340-9351.
26. Ramsden, M.; Kotilinek, L.; Forster, C.; Paulson, J.; McGowan, E.; SantaCruz, K.; Guimaraes, A.; Yue, M.; Lewis, J.; Carlson, G.; Hutton, M.; Ashe, K.H. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J. Neurosci., 2005, 25, 10637-10647.
27. Lewis, J.; Dickson, D.W.; Lin, W.L.; Chisholm, L.; Corral, A.; Jones, G.; Yen, S.H.; Sahara, N.; Skipper, L.; Yager, D.; Eckman, C.; Hardy, J.; Hutton, M.; McGowan, E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science, 2001, 293, 1487-1491.
28. Ribé, E.M.; Pérez, M.; Puig, B.; Gich, I.; Lim, F.; Cuadrado, M.; Sesma, T.; Catena, S.; Sánchez, B.; Nieto, M.; Gómez-Ramos, P.; Morán, M.A.; Cabodevilla, F.; Samaranch, L.; Ortiz, L.; Pérez, A.; Ferrer, I.; Avila, J.; Gómez-Isla, T. Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. Neurobiol. Dis., 2005, 20, 814-822.
29. Paulson, J.B.; Ramsden, M.; Forster, C.; Sherman, M.A.; McGowan, E.; Ashe, K.H. Amyloid plaque and neurofibrillary tangle pathology in a regulatable mouse model of Alzheimer's disease. Am. J. Pathol., 2008, 173, 762-772.
30. Oddo, S.; Caccamo, A.; Shepherd, J.D.; Murphy, M.P.; Golde, T.E.; Kayed, R.; Metherate, R.; Mattson, M.P.; Akbari, Y.; LaFerla, F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron, 2003, 39, 409-421.
31. Billings, L.M.; Oddo, S.; Green, K.N.; McGaugh, J.L.; LaFerla, F.M. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron, 2005, 45, 675-688.
32. Grueninger, F.; Bohrmann, B.; Czech, C.; Ballard, T.M.; Frey, J.R.; Weidensteiner, C.; von Kienlin, M.; Ozmen, L. Phosphorylation of Tau at S422 is enhanced by Abeta in TauPS2APP triple transgenic mice. Neurobiol. Dis., 2009, 37(2), 294-306.
33. Hardy, J.A.; Higgins, G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science, 1992, 256, 184-185.
34. Wolfe, M.S. Inhibition and modulation of gamma-secretase for Alzheimer's disease. Neurotherapeutics, 2008, 5, 391-398.
35. Dovey, H.F.; John, V.; Anderson, J.P.; Chen, L.Z.; de Saint Andrieu, P.; Fang, L.Y.; Freedman, S.B.; Folmer, B.; Goldbach, E.; Holsztynska, E.J.; Hu, K.L.; Johnson-Wood, K.L.; Kennedy, S.L.; Kholodenko, D.; Knops, J.E.; Latimer, L.H.; Lee, M.; Liao, Z.; Lieberburg, I.M.; Motter, R.N.; Mutter, L.C.; Nietz, J.; Quinn, K.P.; Sacchi, K.L.; Seubert, P.A.; Shopp, G.M.; Thorsett, E.D.; Tung, J.S.; Wu, J.; Yang, S.; Yin, C.T.; Schenk, D.B.; May, P.C.; Altstiel, L.D.; Bender, M.H.; Boggs, L.N.; Britton, T.C.; Clemens, J.C.; Czilli, D.L.; Dieckman-McGinty, D.K.; Droste, J.J.; Fuson, K.S.; Gitter, B.D.; Hyslop, P.A.; Johnstone, E.M.; Li, W.Y.; Little, S.P.; Mabry, T.E.; Miller, F.D.; Audia, J.E. Functional gamma- secretase inhibitors reduce beta-amyloid peptide levels in brain. J. Neurochem., 2001, 76, 173-181.
36. Lanz, T.A.; Himes, C.S.; Pallante, G.; Adams, L.; Yamazaki, S.; Amore, B.; Merchant, K.M. The gamma-secretase inhibitor N-[N- (3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces Abeta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J Pharmacol. Exp. Ther., 2003, 305, 864-871.
37. Lanz, T.A.; Hosley, J.D.; Adams, W.J.; Merchant, K.M. Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma- secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxy- ethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin -7-yl]-L-alaninamide (LY-411575). J. Pharmacol. Exp. Ther., 2004, 309, 49-55.
38. Barten, D.M.; Guss, V.L.; Corsa, J.A.; Loo, A.; Hansel, S.B.; Zheng, M.; Munoz, B.; Srinivasan, K.; Wang, B.; Robertson, B.J.; Polson, C.T.; Wang, J.; Roberts, S.B.; Hendrick, J.P.; Anderson, J.J.; Loy, J.K.; Denton, R.; Verdoorn, T.A.; Smith, D.W.; Felsenstein, K.M. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor. J. Pharmacol. Exp. Ther., 2005, 312, 635-643.
39. Comery, T.A.; Martone, R.L.; Aschmies, S.; Atchison, K.P.; Diamantidis, G.; Gong, X.; Zhou, H.; Kreft, A.F.; Pangalos, M.N.; Sonnenberg-Reines, J.; Jacobsen, J.S.; Marquis, K.L. Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci., 2005, 25, 8898-8902.
40. Best, J.D.; Smith, D.W.; Reilly, M.A.; O'Donnell, R.; Lewis, H.D.; Ellis, S.; Wilkie, N.; Rosahl, T.W.; Laroque, P.A.; Boussiquet- Leroux, C.; Churcher, I.; Atack, J.R.; Harrison, T.; Shearman, M.S. The novel gamma secretase inhibitor N-[cis-4-[(4- chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1- trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse. J. Pharmacol. Exp. Ther., 2007, 320, 552-558.
41. Garcia-Alloza, M.; Subramanian, M.; Thyssen, D.; Borrelli, L.A.; Fauq, A.; Das, P.; Golde, T.E.; Hyman, B.T.; Bacskai, B.J. Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY- 411575. Mol. Neurodegener., 2009, 4, 19.
42. Jankowsky, J.L.; Slunt, H.H.; Gonzales, V.; Savonenko, A.V.; Wen, J.C.; Jenkins, N.A.; Copeland, N.G.; Younkin, L.H.; Lester, H.A.; Younkin, S.G.; Borchelt, D.R. Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Med., 2005, 2, e355.
43. Siemers, E.; Skinner, M.; Dean, R.A.; Gonzales, C.; Satterwhite, J.; Farlow, M.; Ness, D.; May, P.C. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma- secretase inhibitor in volunteers. Clin. Neuropharmacol., 2005, 28, 126-132.
44. Martone, R.L.; Zhou, H.; Atchison, K.; Comery, T.; Xu, J.Z.; Huang, X.; Gong, X.; Jin, M.; Kreft, A.; Harrison, B.; Mayer, S.C.; Aschmies, S.; Gonzales, C.; Zaleska, M.M.; Riddell, D.R.; Wagner, E.; Lu, P.; Sun, S.C.; Sonnenberg-Reines, J.; Oganesian, A.; Adkins, K.; Leach, M.W.; Clarke, D.W.; Huryn, D.; Abou-Gharbia, M.; Magolda, R.; Bard, J.; Frick, G.; Raje, S.; Forlow, S.B.; Balliet, C.; Burczynski, M.E.; Reinhart, P.H.; Wan, H.I.; Pangalos, M.N.; Jacobsen, J.S. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma- secretase for the treatment of Alzheimer's disease. J. Pharmacol. Exp. Ther., 2009, 331, 598-608.
45. Eriksen, J.L.; Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH, Golde TE. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J. Clin. Invest., 2003, 112, 440-449.
46. Imbimbo, B.P.; Del Giudice, E.; Cenacchi, V.; Volta, R.; Villetti, G.; Facchinetti, F.; Riccardi, B.; Puccini, P.; Moretto, N.; Grassi, F.; Ottonello, S.; Leon, A. In vitro and in vivo profiling of CHF5022 and CHF5074. Pharmacol. Res., 2007, 55, 318-328.
47. Wilcock, G.K.; Black, S.E.; Hendrix, S.B.; Zavitz, K.H.; Swabb, E.A.; Laughlin, M.A.; and Tarenflurbil Phase II Study Investigators. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol., 2008, 7, 483-493.
48. Williams, M. Progress in Alzheimer's disease drug discovery: an update. Curr. Opin. Investig. Drugs, 2009, 10, 23-34.
49. Pissarnitski, D. Advances in gamma-secretase modulation. Curr. Opin. Drug Discov. Dev., 2007, 10, 392-402.
50. Hills, I.D.; Vacca, J.P. Progress toward a practical BACE-1 inhibitor. Curr. Opin. Drug Discov. Dev., 2007, 10, 383-391.
51. Chang, W.P.; Koelsch, G.; Wong, S.; Downs, D.; Da, H.; Weerasena, V.; Gordon, B.; Devasamudram, T.; Bilcer, G.; Ghosh, A.K.; Tang, J. In vivo inhibition of Abeta production by memapsin 2 (beta-secretase) inhibitors. J. Neurochem., 2004, 89, 1409-1416.
52. Asai, M.; Hattori, C.; Iwata, N.; Saido, T.C.; Sasagawa, N.; Szabó, B.; Hashimoto, Y.; Maruyama, K.; Tanuma, S.; Kiso, Y.; Ishiura, S. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. J. Neurochem., 2006, 96, 533-540.
53. Hussain, I.; Hawkins, J.; Harrison, D.; Hille, C.; Wayne, G.; Cutler, L.; Buck, T.; Walter, D.; Demont, E.; Howes, C.; Naylor, A.; Jeffrey, P.; Gonzalez, M.I.; Dingwall, C.; Michel, A.; Redshaw, S.; Davis, J.B. Oral administration of a potent and selective non- peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. J. Neurochem., 2007, 100, 802-809.
54. Sankaranarayanan, S.; Price, E.A.; Wu, G.; Crouthamel, M.C.; Shi, X.P.; Tugusheva, K.; Tyler, K.X.; Kahana, J.; Ellis, J.; Jin, L.; Steele, T.; Stachel, S.; Coburn, C.; Simon, A.J. In vivo beta- secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1. J. Pharmacol. Exp. Ther., 2008, 324, 957-969.
55. Machauer, R.; Laumen, K.; Veenstra, S.; Rondeau, J.M.; Tintelnot- Blomley, M.; Betschart, C.; Jaton, A.L.; Desrayaud, S.; Staufenbiel, M.; Rabe, S.; Paganetti, P.; Neumann, U. Macrocyclic peptidomimetic beta-secretase (BACE-1) inhibitors with activity in vivo. Bioorg. Med. Chem. Lett., 2009, 19, 1366-1370.
56. Panza, F.; Solfrizzi, V.; Frisardi, V.; Capurso, C.; D'Introno, A.; Colacicco, A.M.; Vendemiale, G.; Capurso, A.; Imbimbo, B.P. Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators. Drugs Aging, 2009, 26, 537-555.
57. Gervais, F.; Paquette, J.; Morissette, C.; Krzywkowski, P.; Yu, M.; Azzi, M.; Lacombe, D.; Kong, X.; Aman, A.; Laurin, J.; Szarek, W.A.; Tremblay, P. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol. Aging, 2007, 28, 537-547.
58. McLaurin, J.; Kierstead, M.E.; Brown, M.E.; Hawkes, C.A.; Lambermon, M.H.L.; Phinney, A.L.; Darabie, A.A.; Cousins, J.E.; French, J.E.; Lan, M.F.; Chen, F.; Wong, S.S.N.; Mount, H.T.J.; Fraser, P.E.; Westaway, D.; St. George-Hyslop, P. Cyclohexanehexol inhibitors of A aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med., 2006, 12, 801-808.
59. Cherny, R.A.; Atwood, C.S.; Xilinas, M.E.; Gray, D.N.; Jones, W.D.; McLean, C.A.; Barnham, K.J.; Volitakis, I.; Fraser, F.W.; Kim, Y.; Huang, X.; Goldstein, L.E.; Moir, R.D.; Lim, J.T.; Beyreuther, K.; Zheng, H.; Tanzi, R.E.; Masters, C.L.; Bush, A.I. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron, 2001, 30, 665-676.
60. Lee, J.Y.; Friedman, J.E.; Angel, I.; Kozak, A.; Koh, J.Y. The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. Neurobiol. Aging, 2004, 25, 1315-1321.
61. Ritchie, C.W.; Bush, A.I.; Mackinnon, A.; Macfarlane, S.; Mastwyk, M.; MacGregor, L.; Kiers, L.; Cherny, R.; Li, Q.X.; Tammer, A.; Carrington, D.; Mavros, C.; Volitakis, I.; Xilinas, M.; Ames, D.; Davis, S.; Beyreuther, K.; Tanzi, R.E.; Masters, C.L. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting A amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial. Arch. Neurol., 2003, 60, 1685-1691.
62. Aisen, P.S.; Gauthier, S.; Vellas, B.; Briand, R.; Saumier, D.; Laurin, J.; Garceau, D. Alzhemed: a potential treatment for Alzheimer's disease. Curr. Alzheimer Res., 2007, 4, 473-478.
63. Lannfelt, L.; Blennow, K.; Zetterberg, H.; Batsman, S.; Ames, D.; Harrison, J.; Masters, C.L.; Targum, S.; Bush, A.I.; Murdoch, R.; Wilson, J.; Ritchie, C.W. Safety, efficacy, and biomarker findings of PBT2 in targeting A as a modifying therapy for Alzheimer's disease: A phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol., 2008, 7, 779-786.
64. Wisniewski, T.; Sadowski, M. Preventing beta-amyloid fibrillization and deposition: beta-sheet breakers and pathological chaperone inhibitors. BMC Neurosci., 2008, 9(Suppl 2), S5.
65. Schenk, D.; Barbour, R.; Dunn, W.; Gordon, G.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Liao, Z.; Lieberburg, I.; Motter, R.; Mutter, L.; Soriano, F.; Shopp, G.; Vasquez, N.; Vandevert, C.; Walker, S.; Wogulis, M.; Yednock, T.; Games, D.; Seubert, P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 1999, 400, 173-177.
66. Janus, C.; Pearson, J.; McLaurin, J.; Mathews, P.M.; Jiang, Y.; Schmidt, S.D.; Chishti, M.A.; Horne, P.; Heslin, D.; French, J.; Mount, H.T.; Nixon, R.A.; Mercken, M.; Bergeron, C.; Fraser, P.E.; St George-Hyslop, P.; Westaway, D. Abeta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature, 2000, 408, 979-82.
67. Morgan, D.; Diamond, D.M.; Gottschall, P.E.; Ugen, K.E.; Dickey, C.; Hardy, J.; Duff, K.; Jantzen, P.; DiCarlo, G.; Wilcock, D.; Connor, K.; Hatcher, J.; Hope, C.; Gordon, M.; Arendash, G.W. Abeta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 2000, 408, 982-985.
68. Senior, K. Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol., 2002, 1, 3.
69. Check, E. Nerve inflammation halts trial for Alzheimer's drug. Nature, 2002, 415, 462.
70. Nicoll, J.A.; Wilkinson, D.; Holmes, C.; Steart, P.; Markham, H.; Weller, R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med., 2003, 9, 448-452.
71. Town, T.; Vendrame, M.; Patel, A.; Poetter, D.; DelleDonne, A.; Mori, T.; Smeed, R.; Crawford, F.; Klein, T.; Tan, J.; Mullan, M. Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's beta-amyloid(1-42). J. Neuroimmunol., 2002, 132, 49-59.
72. Hock, C.; Konietzko, U.; Streffer, J.R.; Tracy, J.; Signorell, A.; Muller-Tillmanns, B.; Lemke, U.; Henke, K.; Moritz, E.; Garcia, E.; Wollmer, M.A.; Umbricht, D.; de Quervain, D.J.; Hofmann, M.; Maddalena, A.; Papassotiropoulos, A.; Nitsch, R.M. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron, 2003, 38, 547-554.
73. Holmes, C.; Boche, D.; Wilkinson, D.; Yadegarfar, G.; Hopkins, V.; Bayer, A.; Jones, R.W.; Bullock, R.; Love, S.; Neal, J.W.; Zotova, E.; Nicoll, J.A. Longterm effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo controlled phase I trial. Lancet, 2008, 372, 216-223.
74. Pride, M.; Seubert, P.; Grundman, M.; Hagen, M.; Eldridge, J.; Black, R.S. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener. Dis., 2008, 5, 194-196.
75. Nikolic, W.V.; Bai, Y.; Obregon, D.; Hou, H.; Mori, T.; Zeng, J.; Ehrhart, J.; Shytle, R.D.; Giunta, B.; Morgan, D.; Town, T.; Tan, J. Transcutaneous beta-amyloid immunization reduces cerebral beta- amyloid deposits without T cell infiltration and microhemorrhage. Proc. Natl. Acad. Sci. USA, 2007, 104, 2507-2512.
76. Obregon, D.; Hou, H.; Bai, Y.; Nikolic, W.V.; Mori, T.; Luo, D.; Zeng, J.; Ehrhart, J.; Fernandez, F.; Morgan, D.; Giunta, B.; Town, T.; Tan, J. CD40L disruption enhances Abeta vaccine-mediated reduction of cerebral amyloidosis while minimizing cerebral amyloid angiopathy and inflammation. Neurobiol. Dis., 2008, 29, 336-353.
77. Bard, F.; Cannon, C.; Barbour, R.; Burke, R.L.; Games, D.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Lieberburg, I.; Motter, R.; Nguyen, M.; Soriano, F.; Vasquez, N.; Weiss, K.; Welch, B.; Seubert, P.; Schenk, D.; Yednock, T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med., 2000, 6, 916-919.
78. DeMattos, R.B.; Bales, K.R.; Cummins, D.J.; Dodart, J.C.; Paul, S.M.; Holtzman, D.M.Peripheral anti-A beta antibody alters CNS and plasma Abeta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA., 2001, 98, 8850-8855.
79. Dodart, J.C.; Bales, K.R.; Gannon, K.S.; Greene, S.J.; DeMattos, R.B.; Mathis, C.; DeLong, C.A.; Wu, S.; Wu, X.; Holtzman, D.M.; Paul, S.M. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci., 2002, 5, 452-457.
80. Bednar, M.M. Anti-amyloid antibody drugs in clinical testing for Alzheimer's disease. IDrugs, 2009, 12, 566-575.
81. Deane, R.; Du Yan, S.; Submamaryan, R.K.; LaRue, B.; Jovanovic, S.; Hogg, E.; Welch, D.; Manness, L.; Lin, C.; Yu, J.; Zhu, H.; Ghiso, J.; Frangione, B.; Stern, A.; Schmidt, A.M.; Armstrong, D.L.; Arnold, B.; Liliensiek, B.; Nawroth, P.; Hofman, F.; Kindy, M.; Stern, D.; Zlokovic, B. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med., 2003, 9, 907-913.
82. Arancio, O.; Zhang, H.P.; Chen, X.; Lin, C.; Trinchese, F.; Puzzo, D.; Liu, S.; Hegde, A.; Yan, S.F.; Stern, A.; Luddy, J.S.; Lue, L.F.; Walker, D.G.; Roher, A.; Buttini, M.; Mucke, L.; Li, W.; Schmidt, A.M.; Kindy, M.; Hyslop, P.A.; Stern, D.M.; Du Yan, S.S. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J., 2004, 23, 4096-4105.
83. Lue, L.F.; Walker, D.G.; Jacobson, S.; Sabbagh, M. Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases. Future Neurol., 2009, 4, 167-177.
84. Caccamo, A.; Fisher, A.; LaFerla, F.M. M1 agonists as a potential disease-modifying therapy for Alzheimer's disease. Curr. Alzheimer Res., 2009, 6, 112-117.
85. Solomon, A.; Kivipelto, M. Cholesterol-modifying strategies for Alzheimer's disease. Expert Rev. Neurother., 2009, 9, 695-709.
86. Landreth, G.; Jiang, Q.; Mandrekar, S.; Heneka, M. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics, 2008, 5, 481-489.
87. Lim, G.P.; Chu, T.; Yang, F.; Beech, W.; Frautschy, S.A.; Cole, G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci., 2001, 21, 8370-8377.
88. Arendash, G.W.; Mori, T.; Cao, C.; Mamcarz, M.; Runfeldt, M.; Dickson, A.; Rezai-Zadeh, K.; Tane, J.; Citron, B.A.; Lin, X.; Echeverria, V.; Potter, H. Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice. J. Alzheimers Dis., 2009, 17, 661-680.
89. Rezai-Zadeh, K.; Arendash, G.W.; Hou, H.; Fernandez, F.; Jensen, M.; Runfeldt, M.; Shytle, R.D.; Tan, J. Green tea epigallocatechin- 3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res., 2008, 1214, 177-187.
90. Town, T.; Laouar, Y.; Pittenger, C.; Mori, T.; Szekely, C.A.; Tan, J.; Duman, R.S.; Flavell, R.A. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat. Med., 2008, 14, 681-687
91. Koronyo-Hamaoui, M.; Ko, M.K.; Koronyo, Y.; Azoulay, D.; Seksenyan, A.; Kunis, G.; Pham, M.; Bakhsheshian, J.; Rogeri, P.; Black, K.L.; Farkas, D.L.; Schwartz, M. Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9. J. Neurochem., 2009, 111, 1409-1424.
92. Oddo, S.; Billings, L.; Kesslak, J.P.; Cribbs, D.H.; LaFerla, F.M. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron, 2004, 43, 321-332.
93. Oddo, S.; Vasilevko, V.; Caccamo, A.; Kitazawa, M.; Cribbs, D.H.; LaFerla, F.M. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem., 2006, 281, 39413-39423.
94. Wilcock, D.M.; Gharkholonarehe, N.; Van Nostrand, W.E.; Davis, J.; Vitek, M.P.; Colton, C.A. Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease. J. Neurosci., 2009, 29, 7957-7965.